← back to search

Subrata Sen

The University of Texas MD Anderson Cancer Center · US
🔎 Find collaborators in Oncology · Cell Biology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Cell Biology
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Microtubule and mitosis dynamics, Cancer-related Molecular Pathways, and Cancer Genomics and Diagnostics.
h-index
48
citations
11,905
works
316
NIH funding
primary concept
Medicine
email

Recent publications

RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer.
2026cited by 1position: contributordoi
Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase 2 blinded biomarker validation and panel discovery study.
2026cited by 0position: contributordoi
An integrated multi-omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid.
2025cited by 3position: contributordoi
Blood-Based microRNA Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma With Lead-Time Trajectory in Prediagnostic Samples
Gastro Hep Advances 2024cited by 11position: contributordoi
eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer.
2024cited by 10position: contributordoi
Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.
2024cited by 2position: contributordoi
Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
Cancer Research Communications 2023cited by 11position: middledoi
Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project.
2023cited by 10position: contributordoi
Data from Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
2023cited by 0position: contributordoi
Supplementary Figure from Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
2023cited by 0position: contributordoi
Supplementary Table 1 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
FIGURE 1 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Figure from Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
2023cited by 0position: contributordoi
Supplementary Figure from Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
2023cited by 0position: contributordoi
FIGURE 2 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Table 1 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Table 2 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Figure 2 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Figure from Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
2023cited by 0position: contributordoi
Supplementary Figure from Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
2023cited by 0position: contributordoi
FIGURE 1 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
FIGURE 2 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Data from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Table 3 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Figure 3 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Table 3 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Figure 1 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Data from Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
2023cited by 0position: contributordoi
Data from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi
Supplementary Table 2 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 46 papers (2020–2026)Michele Yip-Schneider · Indiana University Health38 papers (2022–2023)Anirban Maitra · The University of Texas MD Anderson Cancer Center29 papers (2020–2026) · 27 papers (2020–2026)Kimal Rajapakshe · The University of Texas MD Anderson Cancer Center24 papers (2023–2023)Justin W. Wong · The University of Texas at Dallas24 papers (2023–2024)Alexander Semaan · Association of Maternal and Child Health Programs23 papers (2023–2023)Daniela Nachmanson · University of California, Davis23 papers (2023–2023) · 23 papers (2023–2023)Kajsa E. Affolter · BioEnergetics (United States)23 papers (2023–2023) · 23 papers (2023–2023)Jaewon James Lee · Northern Territory Health Services23 papers (2023–2023)Howard H. Wu · Taipei Veterans General Hospital23 papers (2023–2023)Andrew M. Lowy · San Diego Cardiac Center23 papers (2023–2023)Paola A Guerrero · Cancer Research Center23 papers (2023–2023)Matthew A. Firpo · Thomas Jefferson University Hospital23 papers (2023–2023)Olivier Harismendy · University of California, Davis23 papers (2023–2023)Yasminka A Jakubek · The University of Texas MD Anderson Cancer Center23 papers (2023–2023)Vincent Bernard · Radiation Oncology Associates23 papers (2023–2023)C. Max Schmidt · RWTH Aachen University23 papers (2023–2023)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Cell Biology →